FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC

The US FDA has approved AstraZeneca's Imfinzi (durvalumab), to treat limited-stage small cell lung cancer (LS-SCLC) in the adult population.

Dec 5, 2024 - 06:00
FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
The US FDA has approved AstraZeneca's Imfinzi (durvalumab), to treat limited-stage small cell lung cancer (LS-SCLC) in the adult population.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow